|
Bob Delise joined Trinity more than a decade ago as part of the original leadership team. He has over 15 years experience advising senior executives in the biotechnology and pharmaceutical industries. Bob's clients range from Fortune 100 companies to venture-stage biotechnology concerns and are based throughout the US, Europe and Asia/Pacific. With a focus on specialty markets, he has been involved in the launch of over a dozen biotechnology products including therapies for Cancer, Hematology, Rheumatoid Arthritis, Multiple Sclerosis, Cystic Fibrosis, and Lysosomal Storage Diseases. His practice areas include new product commercialization, licensing and product development, therapeutic area strategies, performance tracking of specialty markets, and forecasting. Bob and his team evaluate over 40 compounds for licensing annually on behalf of Trinity clients. Bob attended Dartmouth College, where he graduated Magna Cum Laude with a degree in Economics. | 